Skip to content
Investing

Denison Mines Investor Profile: Wheeler River, the Phoenix Build and the Road to 2028

Denison Mines is building Phoenix, a high-grade in-situ uranium mine in Saskatchewan, with first output targeted for late 2028. Its assets, latest numbers, funding, risks and the milestones to watch.

Aerial view of the Phoenix in-situ recovery uranium mine construction site at Wheeler River, Saskatchewan, showing civil works of the wellfield on cleared ground beside forest and a lake, as of 28 September 2026.
Photo: Denison Mines

Denison Mines is a Canadian uranium developer whose value rests mainly on one project: Phoenix, a high-grade deposit in northern Saskatchewan that it is building as an in-situ recovery mine. Construction started in earnest in July 2026 and first production is targeted for the second half of 2028. Until then the company earns very little revenue and depends on its cash, uranium holdings and debt markets.

What Denison does and where

Denison is listed in Toronto (DML) and on NYSE American (DNN). Its interests are concentrated in the Athabasca Basin of northern Saskatchewan, where it holds direct ownership in properties covering about 459,000 hectares.

The flagship is the Wheeler River project, in which Denison has an effective 95% interest. Wheeler River contains two main deposits. Phoenix is being developed with in-situ recovery, which pumps a mining solution through the ore body underground rather than digging it out. Gryphon, the second deposit, is planned as a conventional underground mine based on a 2018 pre-feasibility study updated in 2023, and is not yet in development.

Denison Mines: share price, chart and news

Denison also has a portfolio of minority stakes around the McClean Lake mill, one of the largest uranium processing plants in the world.

AssetDenison interestStatus
Wheeler River (Phoenix, Gryphon)95% effectivePhoenix under construction
McClean Lake joint venture and mill22.5%Mill toll-processes Cigar Lake ore; McClean North mining since July 2025
Midwest Main and Midwest A25.17%Engineering studies
Waterbury Lake (THT, Huskie)70.55%Exploration and evaluation
JCU (Millennium, Kiggavik, Christie Lake)50% of JCUExploration and evaluation

Orano Canada operates McClean Lake with the remaining 77.5%. Denison's revenue today is toll-milling income from that mill, C$1.0 million in the third quarter of 2026.

Overhead drone view of the concrete raft slabs and rebar for the Phoenix process plant under construction, as of 28 September 2026.
Overhead drone view of the concrete raft slabs and rebar for the Phoenix process plant under construction, as of 28 September 2026. Photo: Denison Mines

Phoenix: the numbers behind the build

The 2023 feasibility study, with a capital cost update in January 2026, describes a 10-year mine with proven and probable reserves of 56.7 million pounds of U3O8 in 219,000 tonnes grading 11.7%. Output is front-loaded: an average of 8.4 million pounds a year over the first five years, then about 3.0 million pounds a year.

Phoenix study figures (100% basis)

  • C$600m initial capital after the investment decision, plus an estimated C$100m before it
  • US$6.28/lb average cash operating cost
  • US$18.41/lb all-in cost, pre-tax

Using a uranium price range of US$68.89 to US$78.36 a pound from consultant UxC, the updated estimate gives a post-tax net present value of C$1.57 billion at an 8% discount rate and an internal rate of return of 73%. The January update raised initial capital from C$419.4 million in the 2023 study, which cut the expected return from 90%.

Construction was about 24% complete at 30 September 2026. Denison spent C$161.1 million on Phoenix in the first nine months of 2026 and expects about C$278.6 million for the full year, after trimming the construction forecast by C$26.6 million because a flooding-affected start delayed some work.

Latest reported numbers

In the third quarter Denison reported net income of C$81.8 million, almost all of it a non-cash gain on the revaluation of the conversion features in its convertible notes. Over nine months it posted a net loss of C$7.5 million.

Balance sheet at 30 September 2026

  • Cash and equivalents of C$362.7 million, down from C$465.9 million at the end of 2025.
  • 950,000 pounds of physical uranium valued at C$121.0 million, plus 182,004 pounds of concentrate inventory.
  • US$345 million of 4.25% convertible senior notes due 15 September 2031, convertible at US$2.92 a share, with capped calls that lift the effective conversion price to US$4.32.
  • A Bank of Nova Scotia facility for up to C$28.5 million of letters of credit, extended to 31 January 2027.
  • 905,445,408 shares in issue at 4 November 2026, or 920,333,611 fully diluted.

Selling physical uranium is part of the funding plan for Phoenix. Denison sold 750,000 pounds in the second quarter at an average of US$89.17 a pound and has 600,000 pounds committed for delivery from the fourth quarter of 2026 to the second quarter of 2027. It reports firm sales commitments of more than 8 million pounds in total, mostly for delivery after 2028, with talks advanced on more than 5 million pounds more. Customers include North American utilities that run about 50 reactors.

The main risks

  • Construction and schedule. Phoenix relies on a frozen ground barrier, and freeze drilling ran behind over the summer. Weather in northern Saskatchewan limits the working season for many tasks.
  • Cost. The initial capital estimate has already risen once, to C$600 million. Denison's completion figures are estimates and could change.
  • Funding and dilution. The company has no meaningful revenue until Phoenix produces. A shortfall would need new debt, more uranium sales or equity, which would dilute holders of more than 905 million shares.
  • Uranium price. Most future sales are priced on a market-related basis, so revenue will move with the uranium price, in both directions.
  • Earnings noise. Changes in the fair value of the convertible notes, driven by Denison's own share price, can swing reported profit by more than C$100 million a quarter.

What to watch

TimingMilestone
Q4 2026Phoenix North drilling continues; process plant building contractor on site
Q4 2026 to Q2 2027Delivery of 600,000 pounds of committed uranium sales
By end of 2026Phoenix airstrip targeted to open, weather permitting
31 January 2027Maturity of the letters of credit facility
Q1 2027Freeze-hole drilling complete; substation energised
Second half of 2028Targeted first production at Phoenix

The next quarterly test is whether construction spending and progress catch up after the slow summer, and whether Denison adds to its contracted sales book.

Sources

Related stories

Markets

Denison Mines Puts Phoenix Uranium Mine at 24% Complete and Trims Its 2026 Build Spend

Denison Mines' Phoenix uranium mine in Saskatchewan was about 24% built at the end of September and still targets output in the second half of 2028, but a slow start cut C$26.6m…

Investing

Atha Energy: Investor Profile of the Uranium Explorer Behind Nunavut's Angilak Project

Atha Energy explores for uranium at Angilak in Nunavut, in Labrador and in the Athabasca Basin. Its assets, latest reported numbers, cash, share count, main risks and the dates to…

Investing

NexGen Energy Investor Profile: Building Rook I, a Large High-Grade Uranium Mine

NexGen Energy is building Rook I around the Arrow uranium deposit in Saskatchewan. What it owns, the expected cost of the mine, its latest numbers, the funding gap, the risks and…

Investing

Boss Energy Profile: Honeymoon, Alta Mesa and a Year of Transition for the Uranium Producer

Boss Energy mines uranium at Honeymoon in South Australia and owns 30% of Alta Mesa in Texas. It has no debt and a large stockpile, but output falls this year as it changes mining…

Investing

Aya Gold & Silver Corrects Q3 Cash Costs to $14.28 an Ounce After Silver Double Count

Aya Gold & Silver refiled its Q3 MD&A after silver in transit was deducted twice. Zgounder ounces sold rise to 1,392,478 and cash costs fall to $14.28 from $15.51. Revenue and…

Investing

FDA Rejects Summit's Lung Cancer Drug Ivonescimab Over Phase 3 Survival Miss

The FDA has rejected Summit Therapeutics' lung cancer drug ivonescimab, saying slower tumour growth in the phase 3 HARMONi trial was not enough without a clear gain in survival.

Investing

Red Cat Withdraws Its $150m to $180m 2026 Revenue Target After $11.8m Third Quarter

Red Cat Holdings has withdrawn its $150m to $180m revenue target for 2026 after third-quarter sales of $11.8m, blaming slower defence funding. Its quarterly net loss more than…

Investing

Berkshire Reveals $689m Bending Spoons Stake, Doubles Lennar and Trims Bank of America Again

Berkshire Hathaway's third-quarter 13F shows a new Bending Spoons stake worth $689m, a doubled Lennar holding and 27.5 million more Bank of America shares sold, while Apple stayed…